With $37M Investment and New Corporate Partner, San Diego’s Cibus to Develop Enhanced Crop Strains for Europe
News Oct 12, 2009
Under the joint development partnership, Cibus will use its proprietary technology (which offers an alternative approach to inserting foreign genes to create genetically modified crops) to develop new plant traits in five unidentified crops for the European market. As part of the related agreement, Makhteshim-Agan, or MAI, will make its investments based on Cibus’s progress—and gradually acquire a 50.1 percent stake.
Cibus describes its technology, known as Rapid Trait Development System, or RTDS, as a “smart-breeding technology” that introduces desirable genetic traits in a plant by using directed mutagenesis, a process that takes advantage of mechanisms of gene repair. The company says that every time a cell copies its DNA, it makes “scrivener” errors, akin to typographical errors in the genetic code. Such variations are common, and according to Cibus, are part of natural variation. Cibus says its technology uses the DNA repair machinery that corrects such typos, and directs it instead to make changes in a specific way that produces the desired trait in the targeted gene.
Cibus hopes its approach will be acceptable to environmental groups and activists opposed to genetically modified organisms, or GMOs. The European market, in particular, has resisted introduction of genetically modified crops.
Back in 2009, researchers identified a herd of Awassi sheep suffering from "day blindness". As that term implies, these sheep were blind during the day (in bright light) but could see at night, in low-light conditions. After identifying the genetic basis of this blindness, researchers have now successfully used gene therapy to restore their daytime vision.READ MORE
The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.